198 related articles for article (PubMed ID: 7013437)
61. [Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients].
Toi M; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1994 Sep; 21(12):2057-60. PubMed ID: 8085859
[No Abstract] [Full Text] [Related]
62. Osteogenic sarcoma studies by the Cancer and Leukemia Group B.
Cortes EP; Holland JF; Glidewell O
Natl Cancer Inst Monogr; 1981 Apr; (56):207-9. PubMed ID: 7029290
[No Abstract] [Full Text] [Related]
63. [Recurrence of right breast cancer at the thoracic wall successfully treated with intra-arterial infusion of doxorubicin hydrochloride--a case report].
Hasegawa S; Yamamoto Y; Ishiwa N; Yoshikawa T; Morinaga S; Noguchi Y; Matsumoto A; Nishimura J; Okoshi T
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2399-401. PubMed ID: 12484084
[TBL] [Abstract][Full Text] [Related]
64. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer.
Moliterni A; Tarenzi E; Capri G; Terenziani M; Bertuzzi A; Grasselli G; Agresti R; Piotti P; Greco M; Salvadori B; Pilotti S; Lombardi F; Valagussa P; Bonadonna G; Gianni L
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-10-S17-14. PubMed ID: 9374085
[TBL] [Abstract][Full Text] [Related]
65. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
[TBL] [Abstract][Full Text] [Related]
66. [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
Delépine N; Alkallaf S; Cornille H; Markowska B; Delépine G
Ann Med Interne (Paris); 2003 Feb; 154(1):12-24. PubMed ID: 12746655
[TBL] [Abstract][Full Text] [Related]
67. New approaches in administration of anticancer drugs.
Rall DP
Cancer Res; 1969 Dec; 29(12):2471-4. PubMed ID: 5369694
[No Abstract] [Full Text] [Related]
68. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
69. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
Saeki T; Nomizu T; Toi M; Ito Y; Noguchi S; Kobayashi T; Asaga T; Minami H; Yamamoto N; Aogi K; Ikeda T; Ohashi Y; Sato W; Tsuruo T
J Clin Oncol; 2007 Feb; 25(4):411-7. PubMed ID: 17179098
[TBL] [Abstract][Full Text] [Related]
70. Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
Bonadonna G; Rossi A; Tancini G; Bajetta E; Marchini S; Brambilla C; Tesoro Tess JD; Valagussa P; Banfi A; Veronesi U
Cancer Treat Rep; 1981; 65 Suppl 1():61-5. PubMed ID: 7034930
[TBL] [Abstract][Full Text] [Related]
71. [Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
Chen JA
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):202-4. PubMed ID: 8261866
[TBL] [Abstract][Full Text] [Related]
72. A pilot study of a high dose methotrexate regime in the management of advanced breast cancer.
Penney GC; Roberts MM
Clin Oncol; 1980 Dec; 6(4):385-6. PubMed ID: 7460412
[No Abstract] [Full Text] [Related]
73. Chemotherapy for advanced breast cancer.
Khanna NN; Kumar A; Khanna S; Pant GC; Sanyal B
Indian J Cancer; 1981 Mar; 18(1):59-62. PubMed ID: 7262908
[No Abstract] [Full Text] [Related]
74. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Hudis C; Seidman A; Raptis G; Fennelly D; Gilewski T; Baselga J; Theodoulou M; Sklarin N; Moynahan M; Surbone A; Currie V; Lebwohl D; Uhlenhopp M; Crown J; Norton L
Semin Oncol; 1996 Feb; 23(1 Suppl 1):58-64. PubMed ID: 8629040
[TBL] [Abstract][Full Text] [Related]
75. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
[No Abstract] [Full Text] [Related]
76. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K
Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
[No Abstract] [Full Text] [Related]
77. Melphalan and methotrexate in advanced breast cancer.
Priestman TJ; Salaman PF
Cancer Treat Rep; 1978 Dec; 62(12):2111-2. PubMed ID: 751718
[No Abstract] [Full Text] [Related]
78. [Intra-arterial infusion of cancer chemotherapeutic drugs in the treatment of advanced breast cancer (author's transl)].
Yayoi E; Aikawa T; Takatsuka Y; Kaji M; Kotsuma Y; Ogawa M; Kosaki G
Nihon Gan Chiryo Gakkai Shi; 1980 Apr; 15(2):166-75. PubMed ID: 7400645
[No Abstract] [Full Text] [Related]
79. Intensified nutrition as an adjunct to cytotoxic chemotherapy in gynaecological cancer patients.
Nuutinen LS; Kauppila A; Ryhänen P; Niinimäki A; Kivinen S; Saarela M; Pakarinen A; Hollmén A
Clin Oncol; 1982 Jun; 8(2):107-12. PubMed ID: 6809386
[No Abstract] [Full Text] [Related]
80. [Intermittent cytostatic intensive therapy of solid tumors with a combination of four drugs].
Siebner H; Hackethal L
Med Welt; 1973 Feb; 24(5):166-9. PubMed ID: 4617091
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
